Oncopeptides AB (ONPPF)
0.265
0.00 (0.00%)
USD |
OTCM |
May 28, 16:00
Oncopeptides Revenue (Quarterly): 0.26M for Sept. 30, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 0.26M |
| June 30, 2023 | 2.470M |
| March 31, 2023 | 0.1078M |
| December 31, 2022 | 0.0524M |
| September 30, 2022 | |
| June 30, 2022 | 0.8946M |
| Date | Value |
|---|---|
| March 31, 2022 | |
| December 31, 2021 | -2.458M |
| September 30, 2021 | 6.284M |
| June 30, 2021 | 7.896M |
| March 31, 2021 | 2.312M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-2.458M
Minimum
Dec 2021
7.896M
Maximum
Jun 2021
1.980M
Average
0.8946M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
| Abliva AB | -- |
| Karolinska Development AB | 0.0454M |
| Calliditas Therapeutics AB | 28.49M |
| Olink Holding AB | 28.75M |
| BioInvent International AB | 0.5729M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -3.758M |
| Total Expenses (Quarterly) | 3.718M |
| EPS Diluted (Quarterly) | -0.0417 |
| Enterprise Value | 12.46M |
| Profit Margin (Quarterly) | -1.45K% |
| Earnings Yield | -102.3% |
| Normalized Earnings Yield | -102.29 |